Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30493773 | 0.94 | KRAS (0.40) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL25331029 | 0.94 | KRAS (0.40) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL30131061 | 0.94 | JAK1 (0.33) | KRASMAPK3MAPK1 | |
| SCHEMBL30801453 | 0.94 | JAK1 (0.33) | KRASMAPK3MAPK1 | |
| SCHEMBL31677245 | 0.94 | KRAS (0.39) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL30864045 | 0.93 | KRAS (0.39) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL31129339 | 0.93 | KRAS (0.39) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL31129533 | 0.93 | KRAS (0.39) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL25309201 | 0.93 | KRAS (0.39) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL31129721 | 0.93 | KRAS (0.39) | KRASMAPK3MAPK1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024159164-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | KRAS 2/4885MAPK3 1707/4885MAPK1 2123/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | KRAS 1/4885MAPK3 1324/4885MAPK1 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.